Article in European Biotechnology Magazine: Evolving Antibody Innovation

Evolving Antibody Innovation: New frontiers in cancer R&D

Biologics are redefining oncology drug development ever since the invention of hybridoma technology 50 years ago. Over the past 25 years, the FDA's approval of biologic drugs has accelerated sharply, underscoring their critical role. Yet, despite remarkable progress, the urgent need for novel targets remains high.

In our latest article published in European Biotechnology Magazine, our CSO, Prof. Dr. Anton Wellstein, discusses the significant role of biologics in oncology drug discovery and development and the challenges and chances within this evolution. He emphasizes: “To translate these advances into breakthrough therapies, the discovery and development of novel targets beyond the usual suspects becomes the key challenge. We must start with the right targets, and that requires uncompromising quality in molecular and clinical data.”

At Indivumed, we're tackling this need by utilizing high-quality tumor and normal tissue samples with minimal cold ischemia time combined with extensive clinical data, which has shown to be crucial for discovering differentially expressed proteins and gaining novel insights. Our approach aids in identifying therapeutically novel targets for antibody therapeutics, like ADCs and bispecific antibodies.

We are happy to share the article printed in the European Biotechnology Magazine.